Cargando…

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research

In May 2019, the US Food and Drug Administration (FDA) released the Framework for FDA’s Real-World Evidence (RWE) Program, a draft guidance to evaluate the potential use of real-world data in facilitating regulatory decisions. As a result, pharmaceutical companies and medical communities see patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flick, E Dawn, Terebelo, Howard R, Fish, Susan, Kitali, Amani, Mahajan, Vrinda, Nifenecker, Melissa, Sullivan, Kristen, Thaler, Paul, Ussery, Sarah, Grinblatt, David L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Health Outcomes and Economics of Cancer Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400140/ https://www.ncbi.nlm.nih.gov/pubmed/37285045 http://dx.doi.org/10.1093/oncolo/oyad110

Ejemplares similares

Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
por: Mitchell, Aaron P, et al.
Publicado: (2022)

COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry
por: Borno, Hala T, et al.
Publicado: (2022)

Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center
por: Zubiri, Leyre, et al.
Publicado: (2021)

Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective
por: Azoulay, Laurent
Publicado: (2022)

Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020
por: Perera, Nirosha D, et al.
Publicado: (2023)

Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum
por: Lai-Kwon, Julia, et al.
Publicado: (2022)

Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
por: Postmus, Douwe, et al.
Publicado: (2017)

Costs of Cancer Care Across the Disease Continuum
por: Kaye, Deborah R., et al.
Publicado: (2018)

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
por: Choi, Jin G., et al.
Publicado: (2018)

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
por: McArthur, Grant A., et al.
Publicado: (2017)

Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment
por: Ludwig, Heinz, et al.
Publicado: (2020)

Women Who Are Young, Non‐White, and with Lower Socioeconomic Status Report Higher Financial Toxicity up to 1 Year After Breast Cancer Surgery: A Mixed‐Effects Regression Analysis
por: Politi, Mary C., et al.
Publicado: (2020)

Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Zheng, Ying, et al.
Publicado: (2021)

Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta‐Analysis
por: Nielson, Carrie M., et al.
Publicado: (2021)

“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management
por: Shickh, Salma, et al.
Publicado: (2022)

Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID‐19
por: Klein, Isaac A., et al.
Publicado: (2021)

The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors
por: George, Saby, et al.
Publicado: (2021)

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021)

Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act
por: Roth, Michael, et al.
Publicado: (2022)

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States
por: Copher, Ronda, et al.
Publicado: (2022)

Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer
por: Tan, Ruoding, et al.
Publicado: (2022)

Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data
por: Raphael, Jacques, et al.
Publicado: (2022)

Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda
por: Kizub, Darya A, et al.
Publicado: (2022)

The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer
por: Bhatt, Sunil, et al.
Publicado: (2022)

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

Connect MM Registry as a national reference for United States multiple myeloma patients
por: Ailawadhi, Sikander, et al.
Publicado: (2019)

Opioid use prior to elective surgery is strongly associated with persistent use following surgery: an analysis of 14 354 Medicare patients
por: Catchpool, Max, et al.
Publicado: (2019)

Paying for On-Patent Pharmaceuticals: Limit Prices and the Emerging Role of a Pay for Outcomes Approach
por: Fuller, Richard L., et al.
Publicado: (2016)

A Prospective Study on the Incidence and Outcomes of Neonatal Thrombocytopenia at a Tertiary Care Facility in Central Saudi Arabia
por: Eltawel, Mohamed, et al.
Publicado: (2018)

Homecare and Healthcare Utilization Errors Post–Neonatal Intensive Care Unit Discharge
por: Patel, Rupalee, et al.
Publicado: (2017)

Comparative Evaluation of Parental Stress Experiences Up to 2 to 3 Years After Preterm and Term Birth
por: Schuetz Haemmerli, Natascha, et al.
Publicado: (2020)

Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity
por: Tian, Jingru, et al.
Publicado: (2023)

Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE‐AF registry
por: Contreras, Johanna P., et al.
Publicado: (2019)

Development of a prognostic model for overall survival in multiple myeloma using the Connect(®) MM Patient Registry
por: Terebelo, Howard R., et al.
Publicado: (2019)

Regulation of Clinical Research Sponsored by Pharmaceutical Companies: A Proposal
por: Sotelo, Julio
Publicado: (2006)

Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus Registry
por: Plantinga, Laura C, et al.
Publicado: (2016)

Qualitative study of Oncology Clinicians’ Perceptions of Barriers to Offering Clinical Trials to Underserved Populations
por: Perez, Giselle K., et al.
Publicado: (2023)

Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations
por: Hartmann, M, et al.
Publicado: (2003)

Genesis of improved quality in imaging through a national Australian echocardiography registry
por: Eccleston, David, et al.
Publicado: (2022)

Time‐trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF‐STENT Registry
por: Boivin‐Proulx, Laurie‐Anne, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2mdvej8d5painjn7ledmbsqis3